Won-Seok Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Won-Seok Lee has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Huda Yahya Zoghbi
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
2 shared publications Qiankun Zhang
Department of Agricultural Biotechnology, Seoul National University, Seoul, South Korea
2 shared publications- Robert E. Handsaker
Broad Institute
2 shared publications Sang-Kee Kang
Department of Agricultural Biotechnology, Seoul National University, Seoul, South Korea
2 shared publicationsTae-Eun Park
Department of Agricultural Biotechnology, Seoul National University, Seoul, South Korea
2 shared publicationsYou-Kyoung Kim
Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, China
2 shared publications
Latest Publications
- Open Access
Somatic DNA-repeat expansions initiate distinct yet analogous changes in Huntington’s disease cortical and striatal neurons
Huntington’s disease (HD) affects the neocortex and striatum with different timing, severity, and gene-expression changes. These pathologies have long been proposed to involve different pathogenic mechanisms, with one brain area’s degeneration leading to the other’s. Striatal neurons degenerate in HD as their huntingtin ( HTT ) CAG-repeat tracts expand somatically beyond 150 CAGs. Here we find that cortical pyramidal neurons in HD undergo biological changes analogous to those in striatal neurons – the same sequence of pathological phases, with toxicity also commencing at ∼150 CAGs yet then changing their gene expression in distinct ways. Pyramidal neurons’ precise molecular identities, rather than their areal or laminar locations, appeared to determine the extent of this somatic DNA-repeat expansion, which varied up to 20-fold among pyramidal neuron subtypes. Cortical and striatal neurons also shared a key pathological feature: nuclear inclusions of aggregated HTT protein in those nuclei with expansions well beyond 150 CAGs.
Open AccessSomatic DNA-repeat expansions initiate distinct yet analogous changes in Huntington’s disease cortical and striatal neurons
Huntington’s disease (HD) affects the neocortex and striatum with different timing, severity, and gene-expression changes. These pathologies have long been proposed to involve different pathogenic mechanisms, with one brain area’s degeneration leading to the other’s. Striatal neurons degenerate in HD as their huntingtin ( HTT ) CAG-repeat tracts expand somatically beyond 150 CAGs. Here we find that cortical pyramidal neurons in HD undergo biological changes analogous to those in striatal neurons – the same sequence of pathological phases, with toxicity also commencing at ∼150 CAGs yet then changing their gene expression in distinct ways. Pyramidal neurons’ precise molecular identities, rather than their areal or laminar locations, appeared to determine the extent of this somatic DNA-repeat expansion, which varied up to 20-fold among pyramidal neuron subtypes. Cortical and striatal neurons also shared a key pathological feature: nuclear inclusions of aggregated HTT protein in those nuclei with expansions well beyond 150 CAGs.
- Top Cited Papers
- 12 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (785) , eadn4600
Antisense oligonucleotide–mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington’s disease iPSC–derived striatal neurons
Expanded CAG alleles in the huntingtin ( HTT ) gene that cause the neurodegenerative disorder Huntington’s disease (HD) are genetically unstable and continue to expand somatically throughout life, driving HD onset and progression. MSH3, a DNA mismatch repair protein, modifies HD onset and progression by driving this somatic CAG repeat expansion process. MSH3 is relatively tolerant of loss-of-function variation in humans, making it a potential therapeutic target. Here, we show that an MSH3 -targeting antisense oligonucleotide (ASO) effectively engaged with its RNA target in induced pluripotent stem cell (iPSC)–derived striatal neurons obtained from a patient with HD carrying 125 HTT CAG repeats (the 125 CAG iPSC line). ASO treatment led to a dose-dependent reduction of MSH3 and subsequent stalling of CAG repeat expansion in these striatal neurons. Bulk RNA sequencing revealed a safe profile for MSH3 reduction, even when reduced by >95%. Maximal knockdown of MSH3 also effectively slowed CAG repeat expansion in striatal neurons with an otherwise accelerated expansion rate, derived from the 125 CAG iPSC line where FAN1 was knocked out by CRISPR-Cas9 editing. Last, we created a knock-in mouse model expressing the human MSH3 gene and demonstrated effective in vivo reduction in human MSH3 after ASO treatment. Our study shows that ASO-mediated MSH3 reduction can prevent HTT CAG repeat expansion in HD 125 CAG iPSC–derived striatal neurons, highlighting the therapeutic potential of this approach.
- 12 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (785) , eadn4600
Top Cited PapersAntisense oligonucleotide–mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington’s disease iPSC–derived striatal neurons
Expanded CAG alleles in the huntingtin ( HTT ) gene that cause the neurodegenerative disorder Huntington’s disease (HD) are genetically unstable and continue to expand somatically throughout life, driving HD onset and progression. MSH3, a DNA mismatch repair protein, modifies HD onset and progression by driving this somatic CAG repeat expansion process. MSH3 is relatively tolerant of loss-of-function variation in humans, making it a potential therapeutic target. Here, we show that an MSH3 -targeting antisense oligonucleotide (ASO) effectively engaged with its RNA target in induced pluripotent stem cell (iPSC)–derived striatal neurons obtained from a patient with HD carrying 125 HTT CAG repeats (the 125 CAG iPSC line). ASO treatment led to a dose-dependent reduction of MSH3 and subsequent stalling of CAG repeat expansion in these striatal neurons. Bulk RNA sequencing revealed a safe profile for MSH3 reduction, even when reduced by >95%. Maximal knockdown of MSH3 also effectively slowed CAG repeat expansion in striatal neurons with an otherwise accelerated expansion rate, derived from the 125 CAG iPSC line where FAN1 was knocked out by CRISPR-Cas9 editing. Last, we created a knock-in mouse model expressing the human MSH3 gene and demonstrated effective in vivo reduction in human MSH3 after ASO treatment. Our study shows that ASO-mediated MSH3 reduction can prevent HTT CAG repeat expansion in HD 125 CAG iPSC–derived striatal neurons, highlighting the therapeutic potential of this approach.
- Open Access
- 2 May 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (9)
Cross-species genetic screens identify transglutaminase 5 as a regulator of polyglutamine-expanded ataxin-1
Many neurodegenerative disorders are caused by abnormal accumulation of misfolded proteins. In spinocerebellar ataxia type 1 (SCA1), accumulation of polyglutamine-expanded (polyQ-expanded) ataxin-1 (ATXN1) causes neuronal toxicity. Lowering total ATXN1, especially the polyQ-expanded form, alleviates disease phenotypes in mice, but the molecular mechanism by which the mutant ATXN1 is specifically modulated is not understood. Here, we identified 22 mutant ATXN1 regulators by performing a cross-species screen of 7787 and 2144 genes in human cells and Drosophila eyes, respectively. Among them, transglutaminase 5 (TG5) preferentially regulated mutant ATXN1 over the WT protein. TG enzymes catalyzed cross-linking of ATXN1 in a polyQ-length–dependent manner, thereby preferentially modulating mutant ATXN1 stability and oligomerization. Perturbing Tg in Drosophila SCA1 models modulated mutant ATXN1 toxicity. Moreover, TG5 was enriched in the nuclei of SCA1-affected neurons and colocalized with nuclear ATXN1 inclusions in brain tissue from patients with SCA1. Our work provides a molecular insight into SCA1 pathogenesis and an opportunity for allele-specific targeting for neurodegenerative disorders.
- 2 May 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (9)
Open AccessCross-species genetic screens identify transglutaminase 5 as a regulator of polyglutamine-expanded ataxin-1
Many neurodegenerative disorders are caused by abnormal accumulation of misfolded proteins. In spinocerebellar ataxia type 1 (SCA1), accumulation of polyglutamine-expanded (polyQ-expanded) ataxin-1 (ATXN1) causes neuronal toxicity. Lowering total ATXN1, especially the polyQ-expanded form, alleviates disease phenotypes in mice, but the molecular mechanism by which the mutant ATXN1 is specifically modulated is not understood. Here, we identified 22 mutant ATXN1 regulators by performing a cross-species screen of 7787 and 2144 genes in human cells and Drosophila eyes, respectively. Among them, transglutaminase 5 (TG5) preferentially regulated mutant ATXN1 over the WT protein. TG enzymes catalyzed cross-linking of ATXN1 in a polyQ-length–dependent manner, thereby preferentially modulating mutant ATXN1 stability and oligomerization. Perturbing Tg in Drosophila SCA1 models modulated mutant ATXN1 toxicity. Moreover, TG5 was enriched in the nuclei of SCA1-affected neurons and colocalized with nuclear ATXN1 inclusions in brain tissue from patients with SCA1. Our work provides a molecular insight into SCA1 pathogenesis and an opportunity for allele-specific targeting for neurodegenerative disorders.
- 11 March 2021
- Published by Springer Nature in The EMBO Journal
- Vol. 40 (7) , e106106
Dual targeting of brain region‐specific kinases potentiates neurological rescue in Spinocerebellar ataxia type 1
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 11 March 2021
- Published by Springer Nature in The EMBO Journal
- Vol. 40 (7) , e106106
Dual targeting of brain region‐specific kinases potentiates neurological rescue in Spinocerebellar ataxia type 1
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 1 April 2014
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 10 (3) , 525-534
Polyxylitol-based gene carrier improves the efficiency of gene transfer through enhanced endosomal osmolysis
- 1 April 2014
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 10 (3) , 525-534
Polyxylitol-based gene carrier improves the efficiency of gene transfer through enhanced endosomal osmolysis
- 1 October 2012
- Published by Elsevier in Biomaterials
- Vol. 33 (29) , 7272-7281
Selective stimulation of caveolae-mediated endocytosis by an osmotic polymannitol-based gene transporter
- 1 October 2012
- Published by Elsevier in Biomaterials
- Vol. 33 (29) , 7272-7281
Selective stimulation of caveolae-mediated endocytosis by an osmotic polymannitol-based gene transporter